Tech Transfer eNews Blog
University-Industry Engagement Advisor

SOFIE licenses cancer diagnosis and treatment technology from University Clinic Heidelberg


By Jesse Schwartz
Published: July 3rd, 2019

SOFIE, a developer of molecular targeted diagnostics and radiotherapeutics (“theranostics”) has licensed a technology from University Clinic Heidelberg (UKHD) in Germany that is designed to identify and break down cancer-associated fibroblasts in tumor stroma and irradiate nearby cancer cells.

The tumor stroma is a component of the tumor microenvironment and plays a crucial role in the initiation, progression and metastasis of tumors. The subpopulation of tumor stromal cells responsible for immune evasion and chemotherapy resistance are known as fibroblasts. The UKHD technology, known as fibroblast activation-protein inhibitors (FAPI), can help identify patients whose tumors contain highly active fibroblasts and can help improve radiotherapeutic treatment for those patients.

According to UKHD professor and co-developer Uwe Haberkorn, the technology “may be beneficial for radiation therapy planning, suspicion of false negative findings, staging, identification of primary tumors in patients with cancers of unknown primary, or even therapy in the last-line situation, especially in combination with immunotherapy.”

Philipp Czernin, chief revenue officer at SOFIE, led the negotiations for licensing the technology from UKHD.

“I worked to not only license the FAPI IP, but more importantly, forge a partnership with the scientists and technology transfer practice at Heidelberg University,” says Czernin. “I could not be more excited about developing FAPI’s theranostic potential across a variety of solid tumor indications to positively impact patient diagnosis and care.”

Source: PR Newswire

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment